The global cardiovascular clinical trials market size is calculated at USD 6.30 billion in 2025 and is forecasted to reach around USD 10.62 billion by 2034, accelerating at a CAGR of 5.98% from 2025 to 2034. The North America market size surpassed USD 2.55 billion in 2024 and is expanding at a CAGR of 6.01% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cardiovascular Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cardiovascular Clinical Trials Market Revenue and Volume, by Phase
8.1.1 Phase I
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Phase III
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Phase IV
8.1.4.1. Market Revenue and Volume Forecast
9.1. Cardiovascular Clinical Trials Market Revenue and Volume, by Study Design
9.1.1. Interventional
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Observational
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Expanded Access
9.1.3.1. Market Revenue and Volume Forecast
10.1. Cardiovascular Clinical Trials Market Revenue and Volume, by Indication
10.1.1. Acute Coronary Syndrome
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Coronary Artery Disease
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Ischemic Heart Disease
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Pulmonary Arterial Hypertension
10.1.4.1. Market Revenue and Volume Forecast
10.1.5. Stroke
10.1.5.1. Market Revenue and Volume Forecast
10.1.6. Cardiac Arrhythmias
10.1.6.1. Market Revenue and Volume Forecast
10.1.7. Heart Failure
10.1.7.1. Market Revenue and Volume Forecast
10.1.8. Others
10.1.8.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Phase
11.1.2. Market Revenue and Volume Forecast, by Study Design
11.1.3. Market Revenue and Volume Forecast, by Indication
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Phase
11.1.4.2. Market Revenue and Volume Forecast, by Study Design
11.1.4.3. Market Revenue and Volume Forecast, by Indication
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Phase
11.1.5.2. Market Revenue and Volume Forecast, by Study Design
11.1.5.3. Market Revenue and Volume Forecast, by Indication
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Phase
11.2.2. Market Revenue and Volume Forecast, by Study Design
11.2.3. Market Revenue and Volume Forecast, by Indication
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Phase
11.2.4.2. Market Revenue and Volume Forecast, by Study Design
11.2.4.3. Market Revenue and Volume Forecast, by Indication
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Phase
11.2.5.2. Market Revenue and Volume Forecast, by Study Design
11.2.5.3. Market Revenue and Volume Forecast, by Indication
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Phase
11.2.6.2. Market Revenue and Volume Forecast, by Study Design
11.2.6.3. Market Revenue and Volume Forecast, by Indication
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Phase
11.2.7.2. Market Revenue and Volume Forecast, by Study Design
11.2.7.3. Market Revenue and Volume Forecast, by Indication
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Phase
11.3.2. Market Revenue and Volume Forecast, by Study Design
11.3.3. Market Revenue and Volume Forecast, by Indication
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Phase
11.3.4.2. Market Revenue and Volume Forecast, by Study Design
11.3.4.3. Market Revenue and Volume Forecast, by Indication
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Phase
11.3.5.2. Market Revenue and Volume Forecast, by Study Design
11.3.5.3. Market Revenue and Volume Forecast, by Indication
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Phase
11.3.6.2. Market Revenue and Volume Forecast, by Study Design
11.3.6.3. Market Revenue and Volume Forecast, by Indication
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Phase
11.3.7.2. Market Revenue and Volume Forecast, by Study Design
11.3.7.3. Market Revenue and Volume Forecast, by Indication
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Phase
11.4.2. Market Revenue and Volume Forecast, by Study Design
11.4.3. Market Revenue and Volume Forecast, by Indication
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Phase
11.4.4.2. Market Revenue and Volume Forecast, by Study Design
11.4.4.3. Market Revenue and Volume Forecast, by Indication
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Phase
11.4.5.2. Market Revenue and Volume Forecast, by Study Design
11.4.5.3. Market Revenue and Volume Forecast, by Indication
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Phase
11.4.6.2. Market Revenue and Volume Forecast, by Study Design
11.4.6.3. Market Revenue and Volume Forecast, by Indication
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Phase
11.4.7.2. Market Revenue and Volume Forecast, by Study Design
11.4.7.3. Market Revenue and Volume Forecast, by Indication
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Phase
11.5.2. Market Revenue and Volume Forecast, by Study Design
11.5.3. Market Revenue and Volume Forecast, by Indication
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Phase
11.5.4.2. Market Revenue and Volume Forecast, by Study Design
11.5.4.3. Market Revenue and Volume Forecast, by Indication
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Phase
11.5.5.2. Market Revenue and Volume Forecast, by Study Design
11.5.5.3. Market Revenue and Volume Forecast, by Indication
12.1. IQVIA Inc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. ICON plc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. SGS SA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eli Lilly and Company
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. PPD Inc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Syneos Health
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Caidya
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Worldwide Clinical Trials
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Vial
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Veeda Clinical Research
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample